Oncology and Immuno-oncology
Sygnature Discovery has a proud track record of discovering novel oncology therapeutics, with the delivery of five pre-clinical candidates since 2013 in diverse areas including epigenetics, orthosteric and allosteric kinase inhibitors as well as receptor antagonists. Drawing upon our deep understanding of oncology drug discovery, we can add significant value to your project, expediting its progression through the discovery pipeline, from Target Validation and Lead Optimisation through to candidate nomination and clinical positioning.
Our experienced teams across medicinal chemistry, bioscience, DMPK and computational chemistry deliver an integrated and flexible discovery and translational oncology platform, allowing efficient design, evaluation and development of your novel compounds using physiologically relevant systems, tailored specifically to accelerate your path to clinical evaluation.
Working seamlessly alongside our other therapeutic area experts allows our oncology teams to draw upon considerable additional expertise in the delivery of molecules targeting inflammation, the immune system and neurological conditions, enabling accelerated success in small molecule delivery against immuno-oncology and CNS oncology targets, alongside our expertise in more conventional targeted therapies.
Our scientists work in close collaboration with you to generate robust and tailored in vitro screening cascades, implementing state-of-the-art technologies and orthogonal biophysics platforms to rapidly deliver decision-enabling data. More detailed biology is explored across a variety of cell culture formats including 3D spheroids, primary cells and co-cultures, enabling the design of appropriate focussed experiments for pivotal in vivo evaluation of pharmacokinetic, pharmacodynamic and efficacy readouts of your key compounds. These investigations, coupled with our extensive capabilities in compound design, synthesis and pharmacokinetic optimisation expedite compound triage to focus upon your most promising lead molecules. In addition, we have our own in-house human Blood Donor Panel, allowing easy access to immune and inflammatory cells from volunteer blood.
From early hit finding, including access to our own proprietary compound collections, through to candidate nomination and beyond, Sygnature Discovery offers all the necessary capabilities to support your most challenging oncology projects. We’d be delighted to discuss how we could work together to make a meaningful difference to the lives of cancer patients.
Oncology Platform Highlights
We have a range of in vitro assays readily available to support your oncology programs, including:
Immuno-oncology Platform Highlights
- In-House Blood Donor Panel
- Multiplex Flow Cytometry
- Cytokine release assays
- Immune Cell Functional Assays
Oncology Success Stories
Read about some of our successes in oncology therapeutics in the following case studies:
Corcept Therapeutics – Gluticocorticoid receptor antagonists
CellCentric – EP300/CBP inhibitors
Fragment-based hit discovery and optimisation against BRD3